



A new microRNA (miRNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity…
A new test could reliably detect early increases in prostate specific antigen (PSA) levels - a biomarker commonly used to measure the recurrence of prostate cancer - in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes…
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer…
Researchers have identified a novel, dual-platform technology, the On-Q-ity Circulating Cancer Capture and Characterisation Chip (C5), which they believe is more efficient than the commonly used single-platform device in identifying circulating tumour cells (CTCs) in breast cancer…
Cassini sends back postcards of Saturn moons
A picture-perfect pure-disc galaxy